Congratulations on SBK’s First R&D Product Approval

On June 28, the Chemical Class 2.2 Novel Drug, Chloral Hydrate Syrup, developed jointly by Chengdu Shibeikang Biomedical Technology Co., Ltd. and Hainan Pengkang Pharmaceutical Co., Ltd., received production approval from the National Medical Products Administration with National Drug Approval No. H20240034. This product is part of the first batch of pediatric drugs encouraged by the government that is developed to address urgent clinical needs.

As a Class 2 improved new drug approved under the central government’s “Four Strictest” drug safety criteria, it showcases SBK’s strong technical R&D capabilities. SBK remains committed to its mission of “Empowering Better Health Through Inclusive Care and Support”, driven by clinical needs, and focused on original and differentiated innovation. This approval marks a key milestone in accelerating the advancement of our therapeutic pipeline and expanding the company’s portfolio.